Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT07449702 is registered in ClinicalTrials.gov with Oruka Therapeutics, Inc. as lead sponsor.

NCT NCT07449702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07449702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Oruka Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 23, 2026
Completion date
July 31, 2030
Enrollment
240 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis